Trichostatin A induces apoptotic cell death of HeLa cells in a Bcl-2 and oxidative stress-dependent manner

International Journal of Oncology

Volumn 42, Issue 1, 2013, Pages 359-366

  You, Bo Ra ^a   Park, Woo Hyun ^a  

^a Chonbuk National University   (South Korea)

Author keywords

Apoptosis; HeLa; Histone deacetylase; Reactive oxygen species; Trichostatin A

Indexed keywords

ACETYLCYSTEINE; CASPASE 3; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; FLUORESCEIN ISOTHIOCYANATE; GLUTATHIONE; HISTONE DEACETYLASE; LIPOCORTIN 5; OXYGEN; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; TRICHOSTATIN A;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GENE SILENCING; HELA CELL; HUMAN; HUMAN CELL; IC 50; MITOCHONDRIAL MEMBRANE POTENTIAL; OXIDATIVE STRESS; PRIORITY JOURNAL; STAINING;

ACETYLCYSTEINE; ANTIOXIDANTS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL CYCLE; CELL PROLIFERATION; FLOW CYTOMETRY; GLUTATHIONE; HELA CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MEMBRANE POTENTIAL, MITOCHONDRIAL; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING;

EID: 84873625043     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1705     Document Type: Article

References (29)

1. Burgess DJ: Histone modification at the gene level. Nat Rev Cancer 12: 156, 2012.
2. Ganesan A, Nolan L, Crabb SJ and Packham G: Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery. Curr Cancer Drug Targets 9: 963-981, 2009.
3. Lu Z, Luo RZ, Peng H, Huang M, Nishmoto A, Hunt KK, Helin K, Liao WS and Yu Y: E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer. Oncogene 25: 230-239, 2006. (Pubitemid 43083684)
4. Khan O and La Thangue NB: HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 90: 85-94, 2012.
5. Lehmann A, Denkert C, Budczies J, Buckendahl AC, Darb-Esfahani S, Noske A, Muller BM, Bahra M, Neuhaus P, Dietel M, et al: High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer 9: 395, 2009.
6. Wang L, Zou X, Berger AD, Twiss C, Peng Y, Li Y, Chiu J, Guo H, Satagopan J, Wilton A, et al: Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res 1: 62-71, 2009.
7. Vanhaecke T, Papeleu P, Elaut G and Rogiers V: Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr Med Chem 11: 1629-1643, 2004. (Pubitemid 38735799)
8. Marks PA: Discovery and development of SAHA as an anticancer agent. Oncogene 26: 1351-1356, 2007. (Pubitemid 46328465)
9. Lane AA and Chabner BA: Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27: 5459-5468, 2009.
10. Campas-Moya C: Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today 45: 787-795, 2009.
11. Pettazzoni P, Pizzimenti S, Toaldo C, Sotomayor P, Tagliavacca L, Liu S, Wang D, Minelli R, Ellis L, Atadja P, et al: Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells. Free Radic Biol Med 50: 313-322, 2011.
12. Phillip CJ, Giardina CK, Bilir B, Cutler DJ, Lai YH, Kucuk O and Moreno CS: Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells. BMC Cancer 12: 145, 2012.
13. Sweet MJ, Shakespear MR, Kamal NA and Fairlie DP: HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation. Immunol Cell Biol 90: 14-22, 2012.
14. Gong K, Xie J, Yi H and Li W: CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells. Biochem J 443: 735-746, 2012.
15. Duenas-Gonzalez A, Lizano M, Candelaria M, Cetina L, Arce C and Cervera E: Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol Cancer 4: 38, 2005.
16. Anton M, Horky M, Kuchtickova S, Vojtesek B and Blaha O: Immunohistochemical detection of acetylation and phosphorylation of histone H3 in cervical smears. Ceska Gynekol 69: 3-6, 2004. (Pubitemid 38222323)
17. Huang BH, Laban M, Leung CH, Lee L, Lee CK, Salto-Tellez M, Raju GC and Hooi SC: Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 12: 395-404, 2005. (Pubitemid 40520691)
18. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I and Coombes RC: Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 7: 971-976, 2001. (Pubitemid 32708736)
19. Zhang CZ, Zhang HT, Chen GG and Lai PB: Trichostatin A sensitizes HBx-expressing liver cancer cells to etoposide treatment. Apoptosis 16: 683-695, 2011.
20. Meng J, Zhang HH, Zhou CX, Li C, Zhang F and Mei QB: The histone deacetylase inhibitor trichostatin A induces cell cycle arrest and apoptosis in colorectal cancer cells via p53-dependent and -independent pathways. Oncol Rep 28: 384-388, 2012.
21. Martinou JC and Youle RJ: Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell 21: 92-101, 2011.
22. Duan H, Heckman CA and Boxer LM: Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 25: 1608-1619, 2005. (Pubitemid 40280131)
23. Ellis L and Pili R: Histone deacetylase inhibitors: advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals 3: 2411-2469, 2010.
24. Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L and Jaulin C: Histone deacetylase inhibitors and genomic instability. Cancer Lett 274: 169-176, 2009.
25. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X and Marks PA: Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 673-678, 2005. (Pubitemid 40282724)
26. Miriyala S, Spasojevic I, Tovmasyan A, Salvemini D, Vujaskovic Z, St Clair D and Batinic-Haberle I: Manganese superoxide dismutase, MnSOD and its mimics. Biochim Biophys Acta 1822: 794-814, 2012.
27. Hitchler MJ, Wikainapakul K, Yu L, Powers K, Attatippaholkun W and Domann FE: Epigenetic regulation of manganese superoxide dismutase expression in human breast cancer cells. Epigenetics 1: 163-171, 2006.
28. Brechbuhl HM, Kachadourian R, Min E, Chan D and Day BJ: Chrysin enhances doxorubicin-induced cytotoxicity in human lung epithelial cancer cell lines: the role of glutathione. Toxicol Appl Pharmacol 258: 1-9, 2012.
29. Fath MA, Ahmad IM, Smith CJ, Spence J and Spitz DR: Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism. Clin Cancer Res 17: 6206-6217, 2011.